Momenta Pharmaceuticals (MNTA) 11.10 $MNTA
AMAG Pharmaceuticals Announces Appointment of Jim Sulat to Its Board of Directors and the Transition of Chairman Role to Gino Santini
GlobeNewswire - Wed Apr 16, 6:49PM CDT
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced new appointments to its board of directors. Current board member, Gino Santini, has been elected, by unanimous vote, to chairman of the board of directors, effective immediately, taking over for Mike Narachi. Mr. Narachi informed the board that, after eight years of service, he has decided not to stand for re-election at this year's upcoming annual shareholder meeting in May 2014. In addition, James R. Sulat has been elected to serve as a new member of the board of directors, effective immediately.
World Market for Biosimilars to 2017: EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others
M2 - Wed Apr 16, 4:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5qb5x5/the_world_market) has announced the addition of the "The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others)" report to their offering. The World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon alpha, Monoclonal Antibodies, Others), predicts a market of nearly $5 billion dollars in the next five years. It's not the first prediction that has been made about the market for generic forms of biopharmaceutical drugs, but according to this report a multi-billion dollar market for biosimilars will arrive in the next five years. The healthcare organization says it's in almost everyone's interest - payors, governments, providers and patients seeking low-cost alternatives to the most expensive and effective therapies. The generic biologic drug market presents many more challenges than the traditional generic market and regulatory restrictions remain. Generic biological drugs are more difficult to produce and a few firms have the expertise. Unlike generics, they are not the exact same as the brand, they have a similar structure and function. Insulin, blood products and monoclonal antibodies (mAbs) are expected to show the most potential for generic equivalent products with blood products leading in revenues. The EU is the first in the world to have defined a policy and legal framework for biosimilars. Absence of such regulation and biosimilars approval process in other countries, in particular in the United States, can lead to a competitive advantage to the EU biosimilars industry, according to the report. The World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon alpha, Monoclonal Antibodies, Others).contains predictions of biosimilar markets in certain biologic drug segments, as well as market by regions. The report contains specific forecasts for each type of biopharmaceutical and breaks out forecasts by region. Key Topics Covered: 1. Executive Summary 2. Introduction And Overview 3. Biosimilar Pharmaceuticals For Expired Biologic Patents 4. Biosimilar Pharmaceuticals For Future Expired Biologic Patents 5. Issues And Trends 6. Market Summary 7. Corporate Profiles - 3Sbio, Inc - Actavis, Inc. - Apotex, Inc. - Beijing Four Rings Biopharmaceutical Co Ltd - Biocad - Biocon Ltd . - Biopartners Gmbh - Bio Sidus S.A. - Bioxpress Therapeutics S.A - Boehringer Ingelheim Gmbh - Celltrion, Inc. - Dong-A Pharmaceutical - Dr. Reddy'S Laboratories Limited - Epirus Biopharmaceuticals - Gedeon Richter - Harvest Moon Pharmaceuticals Usa, Inc - Hospira, Inc. - Kyowa Hakko Kirin Co., Ltd. - Merck & Company - Momenta Pharmaceuticals Inc - Phage Pharmaceuticals, Inc. - Ranbaxy Laboratories Limited - Reliance Genemedix Plc - Reliance Life Sciences - Samsung Bioepis Co Ltd - Sandoz International Gmbh - Sandoz International Gmbh - Stada Arzneimittel Ag - Teva Pharmaceutical Industries, Ltd. - Wockhardt Ltd. For more information visit http://www.researchandmarkets.com/research/5q...rld_market
Nasdaq stocks posting largest percentage increases
AP - Tue Apr 15, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Momenta Pharmaceuticals Announces Date of First Quarter 2014 Financial Results Conference Call and Webcast
GlobeNewswire - Tue Apr 15, 3:05PM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the first quarter ended March 31, 2014 before the U.S. financial markets open on Tuesday, May 6, 2014.
The Supreme Court Will Decide the Fate of a Blockbuster
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Mon Apr 14, 5:30PM CDT
Recently, Teva Pharmaceuticals lost a patent lawsuit over its multiple sclerosis drug Copaxone, which makes up a crucial 40% of the company's income. However, the U.S. Supreme Court has announced that it will hear Teva's appeal of this Appeals...
Momenta Pharmaceuticals Down 29.9% Since SmarTrend Downtrend Call (MNTA)
Comtex SmarTrend(R) - Fri Apr 11, 10:00AM CDT
SmarTrend identified a Downtrend for Momenta Pharmaceuticals (NASDAQ:MNTA) on March 3rd, 2014 at $14.80. In approximately 1 month, Momenta Pharmaceuticals has returned 29.91% as of today's recent price of $10.37.
2 Oversold Stocks Ready to Bounce Higher
at The Street - Mon Apr 07, 8:34AM CDT
Oversold can always get more oversold, but it's also an area from which a stock can bounce sharply higher.
3 Horrendous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Apr 05, 7:10AM CDT
Ugh, ugh, and ugh. Quite a few stocks got hit hard this week, but few like three especially unlucky health-care stocks. April Fools' Day is over, but shareholders of this week's big losers probably still feel like someone is pulling a prank on them....
26.1% Return Seen to Date on SmarTrend Momenta Pharmaceuticals Call (MNTA)
Comtex SmarTrend(R) - Fri Apr 04, 9:21AM CDT
SmarTrend identified a Downtrend for Momenta Pharmaceuticals (NASDAQ:MNTA) on March 3rd, 2014 at $14.80. In approximately 1 month, Momenta Pharmaceuticals has returned 26.06% as of today's recent price of $10.94.
Momenta Pharmaceuticals Slumps: MNTA Falls 16.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 7:55AM CDT
Momenta Pharma saw a big move last session, as the company’s shares fell by nearly 17% on the day.
Why MannKind, Momenta Pharmaceuticals, and Idera Pharmaceuticals Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Mon Mar 31, 7:30PM CDT
Lately, the stock market has turned on every word from the Federal Reserve, and so this morning's comments from Federal Reserve Chairwoman Janet Yellen received a huge amount of attention from investors Monday. With Yellen offering a much more...
Legal Woes Piling Up for Teva Pharmaceutical Industries Ltd
Cory Renauer, The Motley Fool - Motley Fool - Mon Mar 31, 3:12PM CDT
Editor's Note: Shortly after this article's publication, news outlets reported that the Supreme Court has agreed to a hearing on generic Copaxone. The article has been adjusted to reflect the updated information. Over the past week Teva 's ...
Supreme Court takes up drug company dispute
AP - Mon Mar 31, 8:43AM CDT
WASHINGTON (AP) — The Supreme Court is wading into a patent dispute between rival pharmaceutical companies over a multiple sclerosis treatment.
Supreme Court Ignores Teva Pharmaceuticals Ltd's Pleas for Help
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 28, 1:30PM CDT
Teva Pharmaceuticals is feverishly working to deflect revenue risk tied to the impending patent expiration for its highly popular multiple sclerosis drug Copaxone. The company's attempts to block potential generic biosimilars from coming to market...
Teva upgraded on drug launch
at Investor's Business Daily - Thu Mar 06, 5:39PM CST
The generic-drug maker was upgraded to outperform by Leerink Partners on the rise of its multiple-sclerosis drug. According to the analyst's survey, 40% of users are estimated to switch to Teva Pharmaceutical's (TEVA) new 40-milligram, thrice-weekly...
AMAG Pharmaceuticals Announces Appointment of Jim Sulat to Its Board of Directors and the Transition of Chairman Role to Gino Santini
GlobeNewswire - Wed Apr 16, 6:49PM CDT
AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced new appointments to its board of directors. Current board member, Gino Santini, has been elected, by unanimous vote, to chairman of the board of directors, effective immediately, taking over for Mike Narachi. Mr. Narachi informed the board that, after eight years of service, he has decided not to stand for re-election at this year's upcoming annual shareholder meeting in May 2014. In addition, James R. Sulat has been elected to serve as a new member of the board of directors, effective immediately.
World Market for Biosimilars to 2017: EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others
M2 - Wed Apr 16, 4:54AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5qb5x5/the_world_market) has announced the addition of the "The World Market for Biosimilars, 4th Edition (EPO, G-CSF, HGH, Insulin, Interferon alpha, mAbs, Others)" report to their offering. The World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon alpha, Monoclonal Antibodies, Others), predicts a market of nearly $5 billion dollars in the next five years. It's not the first prediction that has been made about the market for generic forms of biopharmaceutical drugs, but according to this report a multi-billion dollar market for biosimilars will arrive in the next five years. The healthcare organization says it's in almost everyone's interest - payors, governments, providers and patients seeking low-cost alternatives to the most expensive and effective therapies. The generic biologic drug market presents many more challenges than the traditional generic market and regulatory restrictions remain. Generic biological drugs are more difficult to produce and a few firms have the expertise. Unlike generics, they are not the exact same as the brand, they have a similar structure and function. Insulin, blood products and monoclonal antibodies (mAbs) are expected to show the most potential for generic equivalent products with blood products leading in revenues. The EU is the first in the world to have defined a policy and legal framework for biosimilars. Absence of such regulation and biosimilars approval process in other countries, in particular in the United States, can lead to a competitive advantage to the EU biosimilars industry, according to the report. The World Market for Biosimilars (EPO, G-CSF, HGH, Insulin, Interferon alpha, Monoclonal Antibodies, Others).contains predictions of biosimilar markets in certain biologic drug segments, as well as market by regions. The report contains specific forecasts for each type of biopharmaceutical and breaks out forecasts by region. Key Topics Covered: 1. Executive Summary 2. Introduction And Overview 3. Biosimilar Pharmaceuticals For Expired Biologic Patents 4. Biosimilar Pharmaceuticals For Future Expired Biologic Patents 5. Issues And Trends 6. Market Summary 7. Corporate Profiles - 3Sbio, Inc - Actavis, Inc. - Apotex, Inc. - Beijing Four Rings Biopharmaceutical Co Ltd - Biocad - Biocon Ltd . - Biopartners Gmbh - Bio Sidus S.A. - Bioxpress Therapeutics S.A - Boehringer Ingelheim Gmbh - Celltrion, Inc. - Dong-A Pharmaceutical - Dr. Reddy'S Laboratories Limited - Epirus Biopharmaceuticals - Gedeon Richter - Harvest Moon Pharmaceuticals Usa, Inc - Hospira, Inc. - Kyowa Hakko Kirin Co., Ltd. - Merck & Company - Momenta Pharmaceuticals Inc - Phage Pharmaceuticals, Inc. - Ranbaxy Laboratories Limited - Reliance Genemedix Plc - Reliance Life Sciences - Samsung Bioepis Co Ltd - Sandoz International Gmbh - Sandoz International Gmbh - Stada Arzneimittel Ag - Teva Pharmaceutical Industries, Ltd. - Wockhardt Ltd. For more information visit http://www.researchandmarkets.com/research/5q...rld_market
Nasdaq stocks posting largest percentage increases
AP - Tue Apr 15, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Momenta Pharmaceuticals Announces Date of First Quarter 2014 Financial Results Conference Call and Webcast
GlobeNewswire - Tue Apr 15, 3:05PM CDT
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the first quarter ended March 31, 2014 before the U.S. financial markets open on Tuesday, May 6, 2014.
The Supreme Court Will Decide the Fate of a Blockbuster
David Williamson and Michael Douglass, The Motley Fool - Motley Fool - Mon Apr 14, 5:30PM CDT
Recently, Teva Pharmaceuticals lost a patent lawsuit over its multiple sclerosis drug Copaxone, which makes up a crucial 40% of the company's income. However, the U.S. Supreme Court has announced that it will hear Teva's appeal of this Appeals...
Momenta Pharmaceuticals Down 29.9% Since SmarTrend Downtrend Call (MNTA)
Comtex SmarTrend(R) - Fri Apr 11, 10:00AM CDT
SmarTrend identified a Downtrend for Momenta Pharmaceuticals (NASDAQ:MNTA) on March 3rd, 2014 at $14.80. In approximately 1 month, Momenta Pharmaceuticals has returned 29.91% as of today's recent price of $10.37.
2 Oversold Stocks Ready to Bounce Higher
at The Street - Mon Apr 07, 8:34AM CDT
Oversold can always get more oversold, but it's also an area from which a stock can bounce sharply higher.
3 Horrendous Health-Care Stocks This Week
Keith Speights, The Motley Fool - Motley Fool - Sat Apr 05, 7:10AM CDT
Ugh, ugh, and ugh. Quite a few stocks got hit hard this week, but few like three especially unlucky health-care stocks. April Fools' Day is over, but shareholders of this week's big losers probably still feel like someone is pulling a prank on them....
26.1% Return Seen to Date on SmarTrend Momenta Pharmaceuticals Call (MNTA)
Comtex SmarTrend(R) - Fri Apr 04, 9:21AM CDT
SmarTrend identified a Downtrend for Momenta Pharmaceuticals (NASDAQ:MNTA) on March 3rd, 2014 at $14.80. In approximately 1 month, Momenta Pharmaceuticals has returned 26.06% as of today's recent price of $10.94.
Momenta Pharmaceuticals Slumps: MNTA Falls 16.9% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Apr 01, 7:55AM CDT
Momenta Pharma saw a big move last session, as the company’s shares fell by nearly 17% on the day.
Why MannKind, Momenta Pharmaceuticals, and Idera Pharmaceuticals Tumbled Today
Dan Caplinger, The Motley Fool - Motley Fool - Mon Mar 31, 7:30PM CDT
Lately, the stock market has turned on every word from the Federal Reserve, and so this morning's comments from Federal Reserve Chairwoman Janet Yellen received a huge amount of attention from investors Monday. With Yellen offering a much more...
Legal Woes Piling Up for Teva Pharmaceutical Industries Ltd
Cory Renauer, The Motley Fool - Motley Fool - Mon Mar 31, 3:12PM CDT
Editor's Note: Shortly after this article's publication, news outlets reported that the Supreme Court has agreed to a hearing on generic Copaxone. The article has been adjusted to reflect the updated information. Over the past week Teva 's ...
Supreme Court takes up drug company dispute
AP - Mon Mar 31, 8:43AM CDT
WASHINGTON (AP) — The Supreme Court is wading into a patent dispute between rival pharmaceutical companies over a multiple sclerosis treatment.
Supreme Court Ignores Teva Pharmaceuticals Ltd's Pleas for Help
Todd Campbell, The Motley Fool - Motley Fool - Fri Mar 28, 1:30PM CDT
Teva Pharmaceuticals is feverishly working to deflect revenue risk tied to the impending patent expiration for its highly popular multiple sclerosis drug Copaxone. The company's attempts to block potential generic biosimilars from coming to market...
Teva upgraded on drug launch
at Investor's Business Daily - Thu Mar 06, 5:39PM CST
The generic-drug maker was upgraded to outperform by Leerink Partners on the rise of its multiple-sclerosis drug. According to the analyst's survey, 40% of users are estimated to switch to Teva Pharmaceutical's (TEVA) new 40-milligram, thrice-weekly...
